Medical experts led by researchers from the University of the Philippines College of Public Health urgently called for a review of the 13-year-old pneumonia vaccine strategy to protect children against one of the leading killer diseases for kids. The Philippines is ranked fifth worldwide in having the most number of pneumonia deaths.
The highlight of the forum was the new UP-CPH study, which concluded that “a reassessment of PCV use in the country with the inclusion of all three pneumonia vaccine formulations may be warranted.” The three WHO-approved vaccines—PCV13 and two kinds of PCV10: PHiD-CV and SIIL-PCV—differ in their direct protection against serotypes or variations of the bacteria. PCV13, the NIP’s current vaccine, was recommended by the Formulary Executive Council in 2014 based on the locally relevant serotypes. According to WHO, however, evidence suggests that there has been a substantial change in the epidemiology of pneumococcal disease.
The study also considers the economics of PCVs, citing the “potential savings from using a new and possibly more cost-effective formulation, the cost of averting resistant serotypes, and the availability of a new PCV with a different but comparable serotype coverage and lowest vaccine price.”
Source: Healthcare Press (healthcarepress.net)
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: autoindustriya - 🏆 15. / 63 Read more »
Source: carguideph - 🏆 16. / 63 Read more »
Source: inquirerdotnet - 🏆 3. / 86 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: manilabulletin - 🏆 25. / 51 Read more »
Source: cebudailynews - 🏆 8. / 71 Read more »